Apatinib in the Treatment of Advanced Non-squamous Non-small Cell Lung Cancer

Inclusion Criteria: 1. Patients 18 to 70 years of age 2. Documented pathological evidence of advanced non-squamous non-small cell lung cancer with measurable lesions 3. Failure of epidermal-growth-factor receptor (EGFR) TKIs target treatment and second-line or more regimens of chemotherapy 4. Eastern Cooperative Oncology Group (ECOG) performance status between 0 and 1 5. Patients had to have recovered from any toxic effects of therapy 6. Patients with brain/meninges metastasis should keep stable disease for 2 months before randomisation 7. Adequate hematologic and biochemical values were required Exclusion Criteria: 1. Presence of small-cell lung cancer alone or with NSCLC 2. Pregnant or breast-feeding women 3. Severe or uncontrolled systemic disease such as clinically significant hypertension(systolic pressure \> 140 mmHg，diastolic pressure \> 90 mmHg), cardiac ischemia and infarction, ventricular arrhythmias(QT ≥ 440ms) and grade 1 cardiac insufficiency 4. Difficulties in taking pills (inability to swallow tablets,GI tract resection, chronic bacillary diarrhea and intestinal obstruction) 5. Coagulation disfunction,hemorrhagic tendency or receiving anticoagulant therapy 6. ≥ CTCAE 2 pneumorrhagia or ≥ CTCAE 3 hemorrhage in other organs within 4 weeks 7. Bone fracture or wounds that was not cured for a long time 8. Arterial thrombus or phlebothrombosis within 6 months and taking anticoagulant agents 9. Mental diseases and psychotropic substances abuse 10. Previous treatment with an experimental agent within 4 weeks 11. Previous treatment with VEGFR、platelet derived growth factor receptor(PDGFR) TKIS 12. Other coexisting malignant disease (apart from basal-cell carcinoma and carcinoma in situ of uterine cervix)